Premium
Prospective evaluation of omeprazole treatment in reflux oesophagitis refractory to H 2 ‐receptor antagonists
Author(s) -
KOOP H.,
HOTZ J.,
POMMER G.,
KLEIN M.,
ARNOLD R.
Publication year - 1990
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.1990.tb00507.x
Subject(s) - omeprazole , medicine , refractory (planetary science) , gastroenterology , reflux , dose , esophagitis , antagonist , esophageal disease , disease , esophagus , receptor , physics , astrobiology
SUMMARY The efficacy of omeprazole therapy (40 mg daily) in H 2 ‐blocker refractory severe reflux oesophagitis (Grade II‐IV; Savary and Miller classification) was investigated in 61 patients. Mean duration of reflux disease and preceding H 2 ‐antagonist treatment were 4.3 years and 15 months, respectively. Healing rates at 4, 8 and 12 weeks were 48%, 80% and 92%, respectively. There was a correlation between severity of oesophagitis and duration of omeprazole therapy necessary for healing. Three patients (5%) required higher dosages than 40 mg for healing. Symptomatic responses paralleled healing. It is concluded that omeprazole is a highly effective drug for severe reflux oesophagitis not responding to H 2 ‐blocker treatment and that 40 mg daily is the optimal dose.